Bisphosphonate treatment inhibits the growth of prostate cancer cells.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Cancer Research

• Publication date

  2001-03-03

• Fields of study

  Medicine

• Identifiers
  PMID 11289137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.

  2000cited by this paper
• Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.

  1999cited by this paper
• Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.

  1999cited by this paper
• Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL‐6 and MMP‐1 by the Tumoral Environment

  1999cited by this paper
• Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.

  1999cited by this paper
• Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.

  1999cited by this paper
• Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.

  1998cited by this paper
• In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

  1998cited by this paper
• Heterocycle‐Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure‐Activity Relationships in J774 Macrophages

  1998cited by this paper
• Membrane association and targeting of prenylated Ras-like GTPases.

  1998cited by this paper
• Bisphosphonates inhibit IL-6 production by human osteoblast-like cells.

  1998cited by this paper
• Reduction in new metastases in breast cancer with adjuvant clodronate treatment.

  1998cited by this paper
• Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis.

  1998cited by this paper
• Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras

  1998cited by this paper
• Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo.

  1998cited by this paper
• The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease.

  1997cited by this paper
• Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.

  1997influential reference
• How Does Alendronate Inhibit Protein-tyrosine Phosphatases?*

  1997cited by this paper
• Pharmacokinetics of Pamidronate Disodium in Patients with Cancer with Normal or Impaired Renal Function

  1997cited by this paper
• Bisphosphonates in prostate carcinoma

  1997cited by this paper
• Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer.

  1997cited by this paper
• Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice.

  1996cited by this paper
• Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.

  1996cited by this paper
• Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates.

  1996influential reference
• Clodronate decreases the frequency of skeletal metastases in women with breast cancer.

  1996cited by this paper
• 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase.

  1996cited by this paper
• Zoledronate in the treatment of osteolytic bone metastases.

  1996cited by this paper
• Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

  1996cited by this paper
• Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

  1996cited by this paper
• Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures.

  1996cited by this paper
• Human protein tyrosine phosphatase‐σ: Alternative splicing and inhibition by bisphosphonates

  1996cited by this paper
• Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model.

  1996cited by this paper
• Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.

  1996cited by this paper
• Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate.

  1996influential reference
• Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.

  1995cited by this paper
• Effect of osteoblast supernatants on cancer cell migration and invasion.

  1995cited by this paper
• Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

  1995cited by this paper
• Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.

  1994cited by this paper
• Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.

  1993cited by this paper
• Infusion rate andpharmacokinetics ofintravenous pamidronate inthetreatment oftumour-induced hypercalcaemia

  1992cited by this paper
• Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.

  1992cited by this paper
• Pharmacokinetics of pamidronate in patients with bone metastases.

  1992cited by this paper
• The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases

  1991cited by this paper
• Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

  1991cited by this paper
• Mechanisms of lytic and blastic metastatic disease of bone.

  1982cited by this paper

• New oxaliplatin-zoledronate derivatives with potential antitumor activity towards bone tumors and metastases.

  2025cites this paper
• Biomolecular fingerprints of the effect of zoledronic acid on prostate cancer stem cells: Comparison of 2D and 3D cell culture models.

  2024cites this paper
• Synthesis of Mesylated and Tosylated α-Hydroxy-Benzylphosphonates; Their Reactivity and Cytostatic Activity

  2024cites this paper
• Cytotoxic Activity of Distinct Families of Phosphonic Acid Derivatives – A Chemocentric Approach to Assess Their Molecular Action

  2024cites this paper
• Green Approach toward Triazole forming Reactions for Developing Anticancer Drugs.

  2023cites this paper
• γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer

  2023cites this paper
• Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy

  2022cites this paper
• Therapies of bone metastases in castration-resistant prostate cancer

  2022cites this paper
• The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line

  2022cites this paper
• The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation

  2021cites this paper
• Recent advances in bone-targeting nanoparticles for biomedical applications

  2021cites this paper
• Synthesis and preliminary anticancer evaluation of new triazole bisphosphonate-based isoprenoid biosynthesis inhibitors.

  2021cites this paper
• Tämä on rinnakkaistallennettu versio alkuperäisestä julkaisusta

  2020cites this paper
• Tandem Oxidative Pudovik Reaction Using Fe3O4@SiO2‐Metformin‐Cu (II) as an Efficient and Recoverable Catalyst

  2020cites this paper
• In silico exploration of binding of selected bisphosphonate derivatives to placental alkaline phosphatase via docking and molecular dynamics.

  2020cites this paper
• Role of Reactive Oxygen Species in the Cytotoxicity of Arsenic Trioxide and Pamidronate for Human Prostate Cancer Cells.

  2020cites this paper
• Dose-Dependent Effects of Zoledronic Acid on Human Periodontal Ligament Stem Cells: An In Vitro Pilot Study

  2020cites this paper
• New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma.

  2020cites this paper
• Therapeutic Dimensions of Bisphosphonates: A Clinical Update

  2020cites this paper
• Role of intravenous zoledronic acid in management of giant cell tumor of bone- A prospective, randomized, clinical, radiological and electron microscopic analysis.

  2019cites this paper
• Zoledronic acid effects the cell cycle signalling AURKA gene in MDA MB231 breast cancer cells

  2019cites this paper
• Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers

  2019cites this paper
• Alendronate-induced disruption of actin cytoskeleton and inhibition of migration/invasion are associated with cofilin downregulation in PC-3 prostate cancer cells

  2018cites this paper
• Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes

  2018cites this paper
• Synthesis, structural, vibrational, electronic, thermal and Fukui analysis of diethyl (hydroxy(4-methoxyphenyl) methyl) phosphonate

  2018cites this paper
• Zoledronic acid overcomes chemoresistance by sensitizing cancer stem cells to apoptosis

  2018cites this paper
• Functionalization of α-hydroxyphosphonates as a convenient route to N-tosyl-α-aminophosphonates

  2018cites this paper
• Lipid Bilayer-Gated Mesoporous Silica Nanocarriers for Tumor-Targeted Delivery of Zoledronic Acid in Vivo.

  2017cites this paper
• Cyclodextrins: A promising drug delivery vehicle for bisphosphonate.

  2017cites this paper
• The anti-tumor activity of zoledronic acid and synergistic effect of zoledronic acid combination with docetaxel on prostate cancer cell line PC-3 in vitro at clinically achievable concentrations

  2017cites this paper
• SYNERGISTIC CYTOTOXIC EFFECT OF STATINS AND BISPHOSPHONATES ON SQUAMOUS CELL CARCINOMA CELL LINE

  2017cites this paper
• Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells

  2017cites this paper
• Bi(NO3)3.5H2O catalyzed phosphonylation of aldehydes: An efficient route to α-hydroxyphosphonates

  2017cites this paper
• Chirality Sensing of α-Hydroxyphosphonates by N-tert-Butyl Sulfinyl Squaramide.

  2017cites this paper
• Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors.

  2017cites this paper
• Radiation Oncology 4-10-2012 alpha ( V ) beta ( 6 ) integrin expression is induced in the POET and Pten ( pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma

  2017cites this paper
• To date the greenest method for the preparation of α-hydroxyphosphonates from substituted benzaldehydes and dialkyl phosphites

  2017cites this paper
• Combination of a third generation bisphosphonate and replication-competent adenoviruses produces synergistic cytotoxicity on mesothelioma

  2016cites this paper
• Bisphosphonates in Orthopedics: Evidence-based Review of Indications and Adverse Effects

  2016cites this paper
• Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells.

  2016cites this paper
• KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models

  2016cites this paper
• Downregulation of connective tissue growth factor reduces migration and invasiveness of osteosarcoma cells.

  2016cites this paper
• Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth.

  2016cites this paper
• Synthesis of α-aminophosphonates from α-hydroxyphosphonates; a theoretical study

  2016cites this paper
• Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma

  2016cites this paper
• 4. Synthesis of Organophosphines, Phosphonates, and Related Compounds

  2016cites this paper
• Individualization of Adjuvant Therapy After Radical Prostatectomy for Clinically Localized Prostate Cancer: Current Status and Future Directions.

  2016cites this paper
• Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study.

  2016cites this paper
• Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells

  2016cites this paper
• Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines

  2015cites this paper
• Systemic treatment of bone metastases in castration-resistant prostate cancer (CRPC): pre-clinical to clinical point of view

  2015cites this paper
• Systematic Drug Repositioning for a Wide Range of Diseases with Integrative Analyses of Phenotypic and Molecular Data

  2015cites this paper
• Green synthesis and antioxidant activity of novel γ-cyano-α- hydroxyphosphonate derivatives.

  2015cites this paper
• Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages

  2015cites this paper
• The efficiency of Zoledronic acid loaded liposomal nanoparticles on breast cancer: an in vitro study.

  2015cites this paper
• Asymmetric synthesis of α-hydroxymethylphosphonates and phosphonic acids via hydrophosphonylation of aldehydes with chiral H-phosphonate

  2015cites this paper
• Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma.

  2015cites this paper
• Synergistic growth inhibition of PC3 prostate cancer cells with low-dose combinations of simvastatin and alendronate.

  2015cites this paper
• Molecular and pharmacological analysis of extracellular Ca2+-dependent enhancement of anti-tumor effect of zoledoronic acid in human oral cancer cells

  2015cites this paper
• Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).

  2015cites this paper
• Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.

  2015cites this paper
• Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells

  2015cites this paper
• Phosphorylation of C–H bonds of aromatic compounds using metals and metal complexes

  2015cites this paper
• Synthesis and biological evaluation of new bisphosphonate-dextran conjugates targeting breast primary tumor.

  2014cites this paper
• Zoledronic Acid and Leuprorelin Acetate, Alone or in Combination, Similarly Reduce Proliferation and Migration of Prostate Cancer Cells In Vitro

  2014cites this paper
• Prostate cancer.

  2014cites this paper
• Ultrasonicated, Nano-ZnO Catalyzed Green Synthesis of α-Hydroxyphosphonates and their Antioxidant Activity

  2014cites this paper
• The Tumor Microenvironment as Target for New Cancer Therapies

  2014cites this paper
• Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.

  2014cites this paper
• The Effect of Alendronate on Proteome of Hepatocellular Carcinoma Cell Lines

  2014cites this paper
• Mitochondrial permeability transition as target of anticancer drugs.

  2014cites this paper
• Bisphosphonates in Bone Metastatic Setting

  2014cites this paper
• Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: A comparative analysis through time lapse video-microscopy technique

  2014cites this paper
• Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans‐Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer

  2014cites this paper
• Synthesis and characterization of amidate rare-earth metal amides and their catalytic activities toward hydrophosphonylation of aldehydes and unactivated ketones

  2014cites this paper
• Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions

  2014cites this paper
• Development of new self-assembling nanoparticles for the delivery of active agents for the treatment of tumors

  2014cites this paper
• A New Approach to Cancer Therapy: The Tumor Microenvironment as Target

  2014cites this paper
• Nano-TiO 2 catalyzed microwave synthesis of -Hydroxyphosphonates

  2014cites this paper
• Use of bisphosphonates in orthopedic surgery: pearls and pitfalls.

  2014cites this paper
• Ultrasound-Promoted Synthesis of Biologically Active α-Hydroxyphosphonates/ Hydroxyphosphinates Using 1,4-Dimethylpiperazine as a Catalyst

  2014cites this paper
• Applications of nanosystems to anticancer drug therapy (Part II. Dendrimers, micelles, lipid-based nanosystems).

  2013cites this paper
• Radiotherapy for the Treatment of Bone Metastases

  2013cites this paper
• [Corrigendum] Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines.

  2013cites this paper
• STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells.

  2013cites this paper
• ONCOGENE DEPENDENT REGULATION OF MIGRATION AND PROLIFERATION IN HUMAN TUMOR CELLS

  2013cites this paper
• OUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH NON- SMALL CELL LUNG CANCER AND BONE METASTASES

  2013cites this paper
• Repositioning of zoledronic acid for breast cancer using transferrin-conjugated liposome

  2013cites this paper
• Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.

  2013cites this paper
• A copper(I)-catalyzed three-component domino process: assembly of complex 1,2,3-triazolyl-5-phosphonates from azides, alkynes, and H-phosphates.

  2013cites this paper
• [1-Hydroxy-1-(2-hydroxyphenyl)ethyl]phosphonates and -phosphinates: convenient synthesis through intramolecular Abramov reaction and protective activity against influenza A

  2013cites this paper
• E-Factor minimized hydrophosphonylation of aldehydes catalyzed by polystyryl-BEMP under solvent-free conditions.

  2013cites this paper
• Codelivery of zoledronic acid and doublestranded RNA from core-shell nanoparticles

  2013cites this paper
• Mechanistic approach for expeditious and solvent-free synthesis of α-hydroxy phosphonates using potassium phosphate as catalyst

  2013cites this paper
• Zoledronic acid significantly enhances radiation‑induced apoptosis against human fibrosarcoma cells by inhibiting radioadaptive signaling.

  2013cites this paper
• augments the anti-Ph+ leukemia activity of imatinib mesylate The third-generation bisphosphonate Zoledronate synergistically

  2013cites this paper
• A new bisphosphonate derivative, CP, induces gastric cancer cell apoptosis via activation of the ERK1/2 signaling pathway

  2013cites this paper
• Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.

  2013cites this paper
• Zoledronic Acid Reverses the Epithelial–Mesenchymal Transition and Inhibits Self-Renewal of Breast Cancer Cells through Inactivation of NF-κB

  2013cites this paper
• Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells

  2013cites this paper